Evidence map›Paper›PMID 38977697›Full record

ArticleScientific reports2024

Dysregulated gene subnetworks in breast invasive carcinoma reveal novel tumor suppressor genes.

Shivangi Agarwal, Monalisa Parija, Sanoj Naik, Pratima Kumari, Sandip K Mishra, Amit K Adhya, Sushil K Kashaw, Anshuman Dixit

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shivangi AgarwalDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, 470003, India.
Monalisa ParijaInstitute of Life Sciences, Nalco Square, Bhubanesawar, 751023, Odisha, India.
Sanoj NaikInstitute of Life Sciences, Nalco Square, Bhubanesawar, 751023, Odisha, India.
Pratima KumariInstitute of Life Sciences, Nalco Square, Bhubanesawar, 751023, Odisha, India.
Sandip K MishraInstitute of Life Sciences, Nalco Square, Bhubanesawar, 751023, Odisha, India.
Amit K AdhyaAll India Institute of Medical Sciences, Bhubanesawar, 751019, India.
Sushil K KashawDepartment of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, 470003, India.
Anshuman DixitInstitute of Life Sciences, Nalco Square, Bhubanesawar, 751023, Odisha, India. anshumandixit@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast invasive carcinoma (BRCA) is the most malignant and leading cause of death in women. Global efforts are ongoing for improvement in early detection, prevention, and treatment. In this milieu, a comprehensive analysis of RNA-sequencing data of 1097 BRCA samples and 114 normal adjacent tissues is done to identify dysregulated genes in major molecular classes of BRCA in various clinical stages. Significantly enriched pathways in distinct molecular classes of BRCA have been identified. Pathways such as interferon signaling, tryptophan degradation, granulocyte adhesion & diapedesis, and catecholamine biosynthesis were found to be significantly enriched in Estrogen/Progesterone Receptor positive/Human Epidermal Growth Factor Receptor 2 negative, pathways such as RAR activation, adipogenesis, the role of JAK1/2 in interferon signaling, TGF-β and STAT3 signaling intricated in Estrogen/Progesterone Receptor negative/Human Epidermal Growth Factor Receptor 2 positive and pathways as IL-1/IL-8, TNFR1/TNFR2, TWEAK, and relaxin signaling were found in triple-negative breast cancer. The dysregulated genes were clustered based on their mutation frequency which revealed nine mutated clusters, some of which were well characterized in cancer while others were less characterized. Each cluster was analyzed in detail which led to the identification of NLGN3, MAML2, TTN, SYNE1, ANK2 as candidate genes in BRCA. They are central hubs in the protein-protein-interaction network, indicating their important regulatory roles. Experimentally, the Real-Time Quantitative Reverse Transcription PCR and western blot confirmed our computational predictions in cell lines. Further, immunohistochemistry corroborated the results in ~ 100 tissue samples. We could experimentally show that the NLGN3 & ANK2 have tumor-suppressor roles in BRCA as shown by cell viability assay, transwell migration, colony forming and wound healing assay. The cell viability and migration was found to be significantly reduced in MCF7 and MDA-MB-231 cell lines in which the selected genes were over-expressed as compared to control cell lines. The wound healing assay also demonstrated a significant decrease in wound closure at 12 h and 24 h time intervals in MCF7 & MDA-MB-231 cells. These findings established the tumor suppressor roles of NLGN3 & ANK2 in BRCA. This will have important ramifications for the therapeutics discovery against BRCA.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorCell Line, TumorFemaleGene Expression ProfilingGene Regulatory NetworksHumansNeoplasm InvasivenessSignal TransductionER/PR+/HER-2−ER/PR−/HER-2+Hotnet2 clustersImmunohistochemistryTNBCWestern Blot

Identifiers

PMID38977697
PMCPMC11231308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.